home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

802.63 +4.86 (+0.61%)

Streaming Delayed Price Updated: 2:51 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 21, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Is Argenx (ARGX) Stock Down 25% Today? ↗

December 20, 2023

Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock.

Via InvestorPlace

Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 20, 2023

Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.

Via Benzinga

Argenx Dives On Autoimmune Therapy Failure ↗

December 20, 2023

A treatment for a skin-blistering condition failed to beat a placebo.

Via Investor's Business Daily

Stifel Maintains Buy Rating for argenx: Here's What You Need To Know ↗

December 18, 2023

Via Benzinga

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗

December 01, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 20, 2023

Via Benzinga

Why Is European Drugmaker Argenx Stock Sinking Today? ↗

December 20, 2023

Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in...

Via Benzinga

Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

December 20, 2023

Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 20, 2023

Via Benzinga

Analyst Ratings for argenx ↗

November 29, 2023

Via Benzinga

These 2 Stocks Are Falling in a Fading Rally ↗

November 28, 2023

It's been a good month, but the stock market's looking tired.

Via The Motley Fool

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

November 15, 2023

Via Benzinga

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

December 20, 2023

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.

Via Benzinga

Topics Stocks

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

December 20, 2023

From argenx SE

Via GlobeNewswire

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review ↗

December 01, 2023

Software earnings were strong, while the Fed is shifting toward rate cuts.

Via Investor's Business Daily

Topics Economy Stocks

$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today ↗

November 01, 2023

Via Benzinga

Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know ↗

November 30, 2023

Via Benzinga

Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 28, 2023

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

Via Benzinga

Why Is Dutch Pharma Argenx Trading Lower Today? ↗

November 28, 2023

Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia...

Via Benzinga

Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug ↗

November 28, 2023

The company was hoping its drug would make a difference for patients with a rare blood disorder.

Via Investor's Business Daily

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 28, 2023

Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 28, 2023

It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today!

Via InvestorPlace

Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 28, 2023

U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday.

Via Benzinga

Topics Stocks

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

November 28, 2023

From argenx SE

Via GlobeNewswire

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗

November 22, 2023

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

Via Benzinga

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

November 16, 2023

From argenx SE

Via GlobeNewswire

Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth ↗

November 06, 2023

Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth.

Via InvestorPlace

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com